Business Trends– category –
-
FDA Approves Orca-T Precision Treg Cell Therapy, Reducing Chronic GVHD Risk and Boosting Survival in Blood Cancer Patients Undergoing Matched Donor Transplants
AJMC (American Journal of Managed Care) USA Overview The U.S. FDA has approved Orca-T precision Treg cell therapy, designed to reduce the risk of chronic graft-versus-host disease (GVHD) and improve survival rates in blood cancer patient... -
Japan Marks 20th Anniversary of iPSC Discovery with World’s First Regenerative Medicine Product Approvals: Myocardial Cell Sheets for Severe Heart Failure and Neural Progenitor Cell Transplants for Parkinson’s Disease
Japan Science and Technology Agency (JST) Japan Overview Twenty years after Professor Shinya Yamanaka's discovery of iPS cells at Kyoto University in 2006, Japan achieved a global first with the approval of iPSC-derived regenerative medi... -
Century Therapeutics Targets Q4 2026 IND Submission for iPSC-Derived CNTY-813 in Type 1 Diabetes, Advances CAR-iT Cell Therapy CNTY-308 Towards Clinical Trials This Year
Century Therapeutics, Inc. (Press Release) USA Overview Century Therapeutics announced that it has completed its pre-IND meeting with the FDA for CNTY-813, an iPSC-derived cell therapy for Type 1 diabetes, targeting an Investigational Ne... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
CrystalO Biopharma Signs Collaboration and Licensing Deal with Almirall for AI-Driven Skin Disease Drug Discovery, Valued Up to €254.5 Million
Insight, China's Pharmaceutical Industry China Overview CrystalO Biopharma has signed a collaboration and licensing agreement with Almirall, a global biopharmaceutical company, to develop innovative drug candidates for skin diseases. The... -
Aisot Technologies Raises €2.13 Million Seed Extension for AI-Powered Portfolio Intelligence Platform Targeting Institutional Investors
Startupticker.ch Switzerland Overview Zurich-based Aisot Technologies has raised €2.13 million in a Seed extension round for its AI-powered portfolio intelligence platform for institutional investors. Spun off from ETH Zurich, the compan... -
River AI Secures $1.1 Billion in Funding Across Seed and Series A Rounds from NVIDIA, AMD, and Others to Develop Personal AI Stack
Menlo Times USA Overview River AI, a startup developing a new stack for personal AI, has secured $1.1 billion in funding across Series Seed and Series A rounds, led by General Catalyst and AMP PBC, with strategic investment from NVIDIA a... -
Skan AI Raises $63 Million to Enhance Platform for Observing and Modeling Employee Workflows, Launching New Enterprise AI Automation Products
VentureBeat USA Overview Enterprise AI startup Skan AI secured $63 million in Series C funding to enhance its platform, which observes and models how employees perform tasks across software. To address the high failure rate of generative... -
AMD Acquires Taalas to Enhance Compute Solutions for Rapidly Growing AI Inference Market
Globe Newswire USA Overview AMD has announced a definitive agreement to acquire Taalas, a pioneer in specialized AI inference silicon, aiming to strengthen its AI roadmap. This acquisition will enhance AMD's compute solutions for the rap...
